Overview

Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), on Days 1-4, in Combination with Docetaxel, on Day 5, Following Obinutuzumab Pretreatment, on Days -13 and -12. Treatment cycles will be 21 days in duration.

Phase:

Phase 2

Details

Lead Sponsor:

NeoTX Therapeutics Ltd.

Collaborator:

Translational Drug Development

Treatments:

Docetaxel
Obinutuzumab